TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)

October 5, 2026 10:43 AM EDT Send to a Friend
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $110.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login